Ultromics
Ultromics provides FDA-cleared, clinically validated AI to help identify patients with HFpEF and cardiac amyloidosis by analyzing routine echocardiograms.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Ultromics is a company founded at the University of Oxford by leading experts in science and AI, in partnership with the Mayo Clinic in the U.S. and the UK's NHS. It develops AI solutions for cardiovascular imaging diagnostics, with products like EchoGo® for heart failure detection and cardiac amyloidosis screening. The company is backed by investors including Google Ventures, Optum Ventures, and Blue Venture Fund.
History
Ultromics was founded at the University of Oxford by leading experts in science and AI, in partnership with the Mayo Clinic in the U.S. and the UK's NHS. The company is a global leader in AI-powered cardiovascular imaging diagnostics, spun out from the University of Oxford, UK and built on a decade of world-leading research. It is backed by investors including Google Ventures, Optum Ventures, and Blue Venture Fund.
Products and positioning
EchoGo® Heart Failure
Advanced AI for identifying patients with HFpEF.
EchoGo® Amyloidosis
Advanced AI for screening patients with Cardiac Amyloidosis.
Sources5 sources
- 1EchoGo | AI for detection of HFpEF & Cardiac Amyloidosis | Ultromicsultromics.com
- 2Leading Minds in AI and Science | Team Ultromics at Oxford | Ultromicsultromics.com
- 3Careers | Ultromicsultromics.com
- 4AI-Powered Early Detection of Cardiovascular Disease | Ultromicsultromics.com
- 5Ultromics, Ltd. (United Kingdom)wikidata.org
Cite this profile: Cite the canonical profile. /brand-wiki/ultromics · Editorial policy · How profiles are compiled